Reviewer’s report

Title: RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes.

Version: 0 Date: 03 Oct 2015

Reviewer: Artur Kowalik

Reviewer's report:

The paper is well constructed and takes into consideration functional inactivation of RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma. The study evaluates in detail the RASFF1 gene promoter methylation, variants of RASSF1 gene expression, chromosomal status applying wide range of molecular techniques. Overall, although findings in this study are not high priority in novelty (Oncogene. 2003 Jun 12;22(24):3806-12., already reported similar results), it provides additional evidence in this field and is of value.

Major comments:

However, the results did not find any clinical association with RASSF1 gene status it could be good to add information about KRAS and BRAF (Cancer Lett. 2003 Sep 25;199(2):169-73. ) status and make a comment in this context. Have you tried to do this?

Minor comments:

Page 5, line 77 What does it mean that LOH .... „is rahter frequent” please be more specific

Are the methods appropriate and well described?

If not, please specify what is required in your comments to the authors.

Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.
I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal